Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

Exclusion Criteria

• •Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)
• •Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%
• •Patients with World Health Organization (WHO) class IV status
• •Patients who are pregnant or breast feeding
• •Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%
• •Significant liver dysfunction not due to sarcoidosis
• •Patients with severe other organ disease felt by investigators to impact survival during the course of the study
• •Patients unable to perform the 6 inhalation treatments required for therapy
• •Patients with \< 90 mm Hg Systolic systemic blood pressure will be excluded